


CLAIMS

1. A compound represented by the formula (I):



wherein R⁷ and R²¹, the same or different, represent

- 1) a C₂ to C₂₂ alkoxy group which may have a substituent,
- 2) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
- 3) a C₇ to C₂₂ aralkyloxy group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 5) RC(=Y)-O-, wherein Y represents an oxygen atom or sulfur atom, and R represents
 - a) a hydrogen atom,
 - b) a C₂ to C₂₂ alkyl group which may have a substituent,
 - c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
 - d) a C₆ to C₁₄ aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C_7 to C_{22} aralkyl group which may have a substituent,

g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

h) a C_1 to C_{22} alkoxy group which may have a substituent,

i) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

j) a C_6 to C_{14} aryloxy group which may have a substituent,

k) a C_3 to C_{14} cycloalkyl group which may have a substituent,

l) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

6) $R^{S1}R^{S2}R^{S3}SiO-$, wherein R^{S1} , R^{S2} and R^{S3} , the same or different, represent

a) a C_1 to C_6 alkyl group or

b) a C_6 to C_{14} aryl group,

7) a halogen atom,

8) $R^{N1}R^{N2}N-R^M-$, wherein R^M represents

a) a single bond,

b) $-CO-O-$,

c) $-SO_2-O-$,

d) $-CS-O-$ or

e) $-CO-NR^{N3}-$, wherein R^{N3} represents a hydrogen atom or a C_1 to C_6 alkyl group which may have a

substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom, and R^{N1} and R^{N2} , the same or different, represent

- a) a hydrogen atom,
- b) a C_1 to C_{22} alkyl group which may have a substituent,
- c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
- d) an aliphatic C_2 to C_{22} acyl group which may have a substituent,
- e) an aromatic C_7 to C_{15} acyl group which may have a substituent,
- f) a C_6 to C_{14} aryl group which may have a substituent,
- g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- h) a C_7 to C_{22} aralkyl group which may have a substituent,
- i) a C_1 to C_{22} alkylsulfonyl group which may have a substituent,
- j) a C_6 to C_{14} arylsulfonyl group which may have a substituent,
- k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,
- l) a 5-membered to 14-membered heteroaralkyl

group which may have a substituent,

m) a C₃ to C₁₄ cycloalkyl group which may have a substituent or

n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

9) R^{N4}SO₂-O-, wherein R^{N4} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) a C₆ to C₁₄ aryl group which may have a substituent,

c) a C₁ to C₂₂ alkoxy group which may have a substituent,

d) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,

e) a C₆ to C₁₄ aryloxy group which may have a substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

10) (R^{N5}O)₂PO-O-, wherein R^{N5} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,

c) a C₆ to C₁₄ aryl group which may have a

substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,


e) a C₇ to C₂₂ aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

11) (R^{N1}R^{N2}N)₂PO-O-, wherein R^{N1} and R^{N2} are the same as defined above or

12) (R^{N1}R^{N2}N)(R^{N5}O)PO-O-, wherein R^{N1}, R^{N2} and R^{N5} are the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

2. The compound according to claim 1 represented by the formula (I-a):



wherein R^{7a} and R^{21a}, the same or different, represent

1) a C₂ to C₂₂ alkoxy group which may have a substituent,

2) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,

3) a C₇ to C₂₂ aralkyloxy group which may have a substituent,

4) R^aC(=Y^a)-O-, wherein Y^a represents an oxygen atom or

sulfur atom, and R^a represents

- a) a hydrogen atom,
 - b) a C_2 to C_{22} alkyl group which may have a substituent,
 - c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
 - d) a C_6 to C_{14} aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C_7 to C_{22} aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - h) a C_1 to C_{22} alkoxy group which may have a substituent,
 - i) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
 - j) a C_6 to C_{14} aryloxy group which may have a substituent or
 - k) a 3-membered to 14-membered heteroaryloxy group which may have a substituent,
- 5) $R^{an1}R^{an2}N-CO-O-$, wherein R^{an1} and R^{an2} , the same or different, represent
- a) a hydrogen atom,
 - b) a C_1 to C_{22} alkyl group which may have a substituent,
 - c) an unsaturated C_2 to C_{22} alkyl group which

may have a substituent,

d) a C₆ to C₁₄ aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C₇ to C₂₂ aralkyl group which may have a substituent,

g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{an1} and R^{an2} together in combination with the nitrogen atom to which R^{an1} and R^{an2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

h) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

i) a C₃ to C₁₄ cycloalkyl group which may have a substituent or

j) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

6) R^{an1}R^{an2}N-SO₂-O-, wherein R^{an1} and R^{an2} are the same as defined above,

7) R^{an1}R^{an2}N-CS-O-, wherein R^{an1} and R^{an2} are the same as defined above,

8) R^{an4}SO₂-O-, wherein R^{an4} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) a C₆ to C₁₄ aryl group which may have a substituent,

c) a C₁ to C₂₂ alkoxy group which may have a

substituent,

d) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,

e) a C₆ to C₁₄ aryloxy group which may have a substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

9) (R^{an5}O)₂PO-O-, wherein R^{an5} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,

c) a C₆ to C₁₄ aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,

e) a C₇ to C₂₂ aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) (R^{an1}R^{an2}N)₂-PO-O-, wherein R^{an1} and R^{an2} are the same as defined above or

11) (R^{an1}R^{an2}N)(R^{an5}O)PO-O-, wherein R^{an1}, R^{an2} and R^{an5} are the same as defined above; or a pharmacologically


acceptable salt thereof, or a hydrate of those.

3. The compound according to claim 1, wherein R^7 and/or R^{21} represent a C_7 to C_{22} aralkyloxy group which may have a substituent, $RC(=Y)-O-$, wherein Y and R are the same as defined above or $R^{N1}R^{N2}N-R^M-$, wherein R^M represents

a) $-CO-O-$ or


b) $-CS-O-$, and R^{N1} and R^{N2} are the same as defined above, provided that, the leftmost bond in a) and b) is bonded to the nitrogen atom; or a pharmacologically acceptable salt thereof, or a hydrate of those.

4. The compound according to claim 1, wherein R^{N1} and R^{N2} , the same or different, represent a C_1 to C_6 alkyl group or C_6 to C_{14} aryl group, or form, together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, a non-aromatic heterocyclic group selected from the group consisting of:




or a pharmacologically acceptable salt thereof, or a hydrate of those.

5. The compound according to claim 2 represented by the formula (I-b):



wherein R^{7b} and R^{21b} , the same or different, represent a C_7 to C_{22} aralkyloxy group which may have a substituent, or $R^b-C(=Y^b)-O-$, wherein Y^b represents an oxygen atom or sulfur atom, and R^b , the same or different, represents

- a) a hydrogen atom,
- b) a C_2 to C_6 alkyl group which may have a substituent,
- c) a C_6 to C_{14} aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- e) a C_7 to C_{10} aralkyl group which may have a substituent,
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- h) a group of the formula (III):



wherein A) n represents an integer of 0 to 4,

X_b represents

- i) $-\text{CHR}^{\text{bN4}}-$,
- ii) $-\text{NR}^{\text{bN5}}-$,
- iii) $-\text{O}-$,
- iv) $-\text{S}-$,
- v) $-\text{SO}-$ or
- vi) $-\text{SO}_2-$,

R^{bN1} represents

- i) a hydrogen atom or
- ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{bN2} represents

- i) a hydrogen atom or
- ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{bN3} and R^{bN4} , the same or different, represent

- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- iv) a C_6 to C_{14} aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C_7 to C_{10} aralkyl group which may have a substituent,

vii) a C₃ to C₈ cycloalkyl group which may have a substituent,

viii) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

xi) -NR^{bn6}R^{bn7}, wherein R^{bn6} and R^{bn7}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or

xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bn3} and R^{bn4} together in combination with the carbon atom to which R^{bn3} and R^{bn4} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and R^{bn5} represents

i) a hydrogen atom,

ii) a C₁ to C₆ alkyl group which may have a substituent,

iii) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,

iv) a C₆ to C₁₄ aryl group which may have a substituent,

v) a 5-membered to 14-membered heteroaryl group which may have a substituent,

vi) a C₇ to C₁₀ aralkyl group which may have a substituent,

vii) a C₃ to C₈ cycloalkyl group which may have a substituent,

viii) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bn3} and R^{bn5} together in combination with the nitrogen atom to which R^{bn3} and R^{bn5} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

B)

X_b, n, R^{bn3}, R^{bn4} and R^{bn5} represent the same group as defined above, and R^{bn1} and R^{bn2} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bn1} and R^{bn2} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,


C)

X_b, n, R^{bn2}, R^{bn4} and R^{bn5} represent the same group as defined above, and R^{bn1} and R^{bn3} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bn1} and R^{bn3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

X_b , n , R^{bN1} , R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN2} and R^{bN3} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN2} and R^{bN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



wherein R^{bN8} and R^{bN9} , the same or different, represent


- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) a C_6 to C_{14} aryl group which may have a substituent,
- iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- v) a C_7 to C_{10} aralkyl group which may have a substituent or
- vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

6. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a1}C(=Y^{a1})-O-$, wherein Y^{a1} represents an oxygen atom or sulfur atom, and R^{a1}

represents

- 1) a hydrogen atom,
- 2) a C₂ to C₆ alkyl group which may have a substituent,
- 3) a C₆ to C₁₀ aryl group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 5) a C₇ to C₁₀ aralkyl group which may have a substituent or
- 6) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

7. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a2}C(=Y^{a2})-O-, wherein Y^{a2} represents an oxygen atom or sulfur atom, and R^{a2} represents a group of the formula (III'):



wherein A) n represents an integer of 0 to 4,
X₁ represents

- 1) -CHR^{aN9}-,
- 2) -NR^{aN10}-,
- 3) -O-,
- 4) -S-,

5) -SO- or

6) -SO₂-,

R^{an6} and R^{an7}, the same or different, represent

1) a hydrogen atom or

2) a C₁ to C₆ alkyl group which may have a substituent,

R^{an8} and R^{an9}, the same or different, represent

1) a hydrogen atom,

2) a C₁ to C₆ alkyl group which may have a substituent,

3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,

4) a C₆ to C₁₄ aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C₇ to C₁₀ aralkyl group which may have a substituent,

7) a C₃ to C₈ cycloalkyl group which may have a substituent,

8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) -NR^{an11}R^{an12}, wherein R^{an11} and R^{an12}, the same or different, represent a hydrogen atom or a C₁ to C₆

alkyl group which may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{an8} and R^{an9} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and R^{an10} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_6 to C_{14} aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C_7 to C_{10} aralkyl group which may have a substituent,
- 7) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 11) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R^{an10} is bonded, and one substituent selected from the


group consisting of R^{aN6}, R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R^{an10} is bonded, and two substituents selected from the group consisting of R^{an6}, R^{an7} and R^{an8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

B) n , X_1 , R^{an7} , R^{an9} and R^{an10} represent the same group as defined above, and R^{an6} and R^{an8} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{an6} and R^{an8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

8. The compound according to claim 6, wherein X_1 represents $-NR^{an10}-$, wherein NR^{an10} is the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

9. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a3}C(=Y^{a3})-O-$, wherein Y^{a3} represents an oxygen atom or sulfur atom, and R^{a3} represents a group of the formula (V):



wherein n represents an integer of 0 to 4,


R^{aN13} represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent, and

R^{aN14} represents

- 1) a hydrogen atom,
- 2) an amino group which may have a substituent,
- 3) a pyridinyl group which may have a substituent,
- 4) a pyrrolidin-1-yl group which may have a substituent,
- 5) a piperidin-1-yl group which may have a substituent,
- 6) a morpholin-4-yl group which may have a substituent or
- 7) a piperazin-1-yl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

10. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a4}CO-O-$, wherein R^{a4} represents a group of the formula (VI):



wherein n_1 and n_2 , the same or different, represent an

integer of 0 to 4,

X_2 represents

- 1) $-\text{CHR}^{\text{aN17}}-$,
- 2) $-\text{NR}^{\text{aN18}}-$,
- 3) $-\text{O}-$,
- 4) $-\text{S}-$,
- 5) $-\text{SO}-$ or
- 6) $-\text{SO}_2-$,

R^{aN15} represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent,

R^{aN16} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent,

R^{aN17} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_6 to C_{14} aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C₇ to C₁₀ aralkyl group which may have a substituent,

7) a C₃ to C₈ cycloalkyl group which may have a substituent,

8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) -NR^{an19}R^{an20}, wherein R^{an19} and R^{an20}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or

11) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and R^{an18} represents

1) a hydrogen atom,

2) a C₁ to C₆ alkyl group which may have a substituent,

3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,

4) a C₆ to C₁₄ aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C₇ to C₁₀ aralkyl group which may have a substituent,

7) a C₃ to C₈ cycloalkyl group which may have


a substituent,

8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

11. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a5}CO-O-, wherein R^{a5} represents a group of the formula (VII):



wherein n₃ represents 1 or 2,

R^{aN21} represents

1) a hydrogen atom or

2) a C₁ to C₆ alkyl group which may have a substituent, and


R^{aN22} represents

1) a hydrogen atom or

2) a C₁ to C₆ alkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

12. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a6}CO-O-, wherein R^{a6} represents a

group of the formula (VIII):



wherein n_1 and n_2 , the same or different, represent an integer of 0 to 4,

X_3 represents

- 1) $-\text{CHR}^{\text{aN}25}-$,
- 2) $-\text{NR}^{\text{aN}26}-$,
- 3) $-\text{O}-$,
- 4) $-\text{S}-$,
- 5) $-\text{SO}-$ or
- 6) $-\text{SO}_2-$,

$\text{R}^{\text{aN}23}$ represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent,

$\text{R}^{\text{aN}24}$ represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent,

$\text{R}^{\text{aN}25}$ represents

- 1) a hydrogen atom,

- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₁ to C₆ alkoxy group which may have a substituent,
- 5) a C₆ to C₁₄ aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 8) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 9) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 10) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 11) -NR^{an27}R^{an28}, wherein R^{an27} and R^{an28}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and R^{an26} represents
 - 1) a hydrogen atom,
 - 2) a C₁ to C₆ alkyl group which may have a substituent,
 - 3) an unsaturated C₂ to C₁₀ alkyl group which

may have a substituent,

4) a C₆ to C₁₄ aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C₇ to C₁₀ aralkyl group which may have a substituent,


7) a C₃ to C₈ cycloalkyl group which may have a substituent,

8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.


13. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a7}CO-O-, wherein R^{a7} represents a group of the formula (IX):



wherein n₄ represents an integer of 1 to 3, and R^{aN29} represents

1) an amino group which may have a substituent,

4) a morpholin-4-yl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.



a substituent,

4) a 3-membered to 8-membered non-aromatic heterocyclic group which may have a substituent,

5) a C₆ to C₁₄ aryl group which may have a substituent,


6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C₇ to C₁₀ aralkyl group which may have a substituent,

8) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

9) a C₄ to C₉ cycloalkylalkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

15. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a9}CO-O-, wherein R^{a9} represents a group of the formula (XI):



wherein n₄ represents an integer of 1 to 3, and R^{aN32} represents

1) a hydrogen atom,

2) a C₁ to C₆ alkyl group which may have a substituent,

3) a C₃ to C₈ cycloalkyl group which may have a substituent,


4) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

5) a C₇ to C₁₀ aralkyl group which may have a substituent,

6) a pyridyl group which may have a substituent or

7) a tetrahydropyranyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

16. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a10}CO-O-, wherein R^{a10} represents a group of the formula (XII):



wherein m₁, m₂, m₃ and m₄, the same or differently, represent 0 or 1,

n₄ represents an integer of 1 to 3, and

R^{aN33} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C₇ to C₁₀ aralkyl group which may have a substituent,


7) a C₃ to C₈ cycloalkyl group which may have a substituent,

8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or


10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

17. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a11}CO-O-, wherein R^{a11} represents a group of the formula (XIII):




wherein m₅ represents an integer of 1 to 3, and n₅ represents 2 or 3; or a pharmacologically acceptable salt thereof, or a hydrate of those.

18. The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a12}CO-O-, wherein R^{a12} represents a group selected from a group consisting of:



or a group selected from a group consisting of



and both of which may have a substituent on the ring;
or a pharmacologically acceptable salt thereof, or a
hydrate of those.

19. The compound according to claim 1, which is
(8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-
pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-
18,19-epoxytricos-8,12,14-trien-11-olide,
(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-
21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-
yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-
olide and (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-
pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-
phenylcarbamoyloxy-18,19-epoxytricos-8,12,14-trien-11-
olide; or a pharmacologically acceptable salt thereof,
or a hydrate of those.

20. A medicine comprising the compound according
to any one of claims 1 to 19, or a pharmacologically

acceptable salt thereof, or a hydrate of those as an active ingredient.

21. A pharmaceutical composition comprising the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof, or a hydrate of those as an active ingredient.

22. The medicine according to claim 20 as an agent for preventing or treating a disease for which gene expression control is effective.

23. The medicine according to claim 20 as an agent for preventing or treating a disease for which suppression of VEGF production is effective.

24. The medicine according to claim 20 as an agent for preventing or treating a disease for which an antiangiogenic effect is effective.

25. The medicine according to claim 20 as an angiogenesis inhibitor.

26. The medicine according to claim 20 as an antitumor agent.

27. The medicine according to claim 20 as a therapeutic agent for treating hemangioma.

28. The medicine according to claim 20 as a cancer metastasis inhibitor.

29. The medicine according to claim 20 as a therapeutic agent for treating retinal neovascularization or diabetic retinopathy.

30. The medicine according to claim 20 as a therapeutic agent for treating inflammatory disease.

31. The medicine according to claim 20 as a therapeutic agent for treating inflammatory diseases consisting of deforamantarthritis, rheumatoid arthritis, psoriasis and delayed hypersensitive reaction.
32. The medicine according to claim 20 as a therapeutic agent for treating atherosclerosis.
33. The medicine according to claim 20 as a therapeutic agent for treating a solid cancer.
34. The medicine according to claim 33, wherein the solid cancer is lung cancer, brain tumor, breast cancer, prostate cancer, ovarian cancer, colon cancer or melanoma.
35. The medicine according to claim 20 as a therapeutic agent for treating leukemia.
36. The medicine according to claim 20 as an antitumor agent based on gene expression control.
37. The medicine according to claim 20 as an antitumor agent based on suppression of VEGF production.
38. The medicine according to claim 20 as an antitumor agent based on an effect of angiogenesis inhibition.
39. A method for preventing or treating a disease for which gene expression control is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.

40. A method for preventing or treating a disease for which suppression of VEGF production is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.
41. A method for preventing or treating a disease for which angiogenesis inhibition is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.
42. Use of the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which gene expression control is effective.
43. Use of the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which suppression of VEGF production inhibition is effective.
44. Use of the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which angiogenesis inhibition is effective.
45. Use of the compound according to any one of claims 1 to 19, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an

agent for preventing or treating a solid cancer.

10/522733

10 Dec'd PCT/PTO 28 JAN 2005

SEQUENCE LISTING

<110> MERCIAN CORPORATION
<110> Eisai Co., Ltd.
<120> Novel bioactive compound
<130> 03043PCT
<160> 2
<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence
<400> 1
atgaactttc tgctgtcttg ggtgcattgg

30

<210> 2
<211> 29
<212> DNA
<213> Artificial Sequence
<400> 2
ctggccttgg tgaggtttgt accgcataa

29

